Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 14/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 14/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21876434 | 0.83 | KEAP1 (0.67) | KEAP1NFE2L2PTGS2SMN1; SMN2 | |
| SCHEMBL3753209 | 0.82 | HTT (0.49) | KEAP1NFE2L2PTGS2SMN1; SMN2 | |
| SCHEMBL31636683 | 0.78 | NOTUM (0.57) | KEAP1NFE2L2PTGS2 | |
| SCHEMBL31284741 | 0.77 | ALDH1A1 (0.45) | KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL27933358 | 0.76 | KEAP1 (0.77) | KEAP1NFE2L2PTGS2 | |
| SCHEMBL23557761 | 0.74 | KEAP1 (0.77) | KEAP1NFE2L2 | |
| SCHEMBL28003857 | 0.74 | KEAP1 (0.72) | KEAP1NFE2L2 | |
| SCHEMBL2886167 | 0.73 | P2RX7 (0.52) | PTGS2 | |
| SCHEMBL22584705 | 0.73 | AR (0.68) | KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL23547195 | 0.73 | KEAP1 (0.60) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101137653-B | Thiazole-4-carboxamide derivatives as MGLUR5 antagonists | HOFFMANN LA ROCHE | 2012-05-09 | — | — | CN | disclosed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| CN-101137653-A | Thiazole-4-carboxamide derivatives as MGLUR5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | CN | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | KEAP1 2650/4885NFE2L2 3431/4885PTGS2 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.